Stay updated on Cabozantinib + Atezolizumab vs Sorafenib in Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib + Atezolizumab vs Sorafenib in Advanced HCC Clinical Trial page.

Latest updates to the Cabozantinib + Atezolizumab vs Sorafenib in Advanced HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe clinical trial page displays the COSMIC-312 study record, including its design, participant criteria, interventions, outcome measures, and locations. It also includes results, record history, and study documents.SummaryDifference100%

- Check18 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide notice announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence.” It appears above the 403 error page rather than providing study information.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s site revision indicator changed from v3.7.1 to v3.7.2; the page remains a 403 error screen.SummaryDifference0.2%

- Check39 days agoChange DetectedThe displayed site revision advances from v3.7.0 to v3.7.1 while the study page remains a 403 error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error page instead of the full study record, effectively blocking access to the COSMIC-312 trial information on that page.SummaryDifference18%

Stay in the know with updates to Cabozantinib + Atezolizumab vs Sorafenib in Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib + Atezolizumab vs Sorafenib in Advanced HCC Clinical Trial page.